Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 1194-1203

  Jones, Gregg S ^a   Yu, Fang ^a   Zeynalzadegan, Ameneh ^a   Hesselgesser, Joseph ^a   Chen, Xiaowu ^a   Chen, James ^a   Jin, Haolun ^a   Kim, Choung U ^a   Wright, Matthew ^a   Geleziunas, Romas ^a   Tsiang, Manuel ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; CAPRAVIRINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; GS 9160; INTEGRASE; LAMIVUDINE; LOPINAVIR; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NELFINAVIR; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MUTATIONAL ANALYSIS; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CATALYTIC DOMAIN; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; MUTATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES;

EID: 62949153971     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00984-08     Document Type: Article

References (47)

1. Baba, M., R. Pauwels, J. Balzarini, P. Herdewijn, E. De Clercq, and J. Desmyter. 1987. Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides of replication of human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 31:1613-1617.
2. Bukrinsky, M., N. Sharova, and M. Stevenson. 1993. Human immunodefi-ciency virus type 1 2-LTR circles reside in a nucleoprotein complex which is different from the preintegration complex. J. Virol. 67:6863-6865.
3. Butler, S. L., M. S. T. Hansen, and F. D. Bushman. 2001. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7:631-634.
4. Chen, X., M. Tsiang, F. Yu, M. Hung, G. S. Jones, A. Zeynalzadegan, X. Qi, H. Jin, C. U. Kim, S. Swaminathan, and J. M. Chen. 2008. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J. Mol. Biol. 380:504-519.
5. Chou, T.-C., and P. Talalay. 1981. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115:207-216.
6. Chou, T.-C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
7. Cooper, D. A., J. Gatell, J. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, J. Chen, R. Isaacs, H. Teppler, B.-Y. Nguyen, and the BENCHMRK-1 Study Group. 2007. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus, abstr. 105aLB, p. 103. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
8. Cooper, D. A., J. Gatell, J. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, X. Xu, R. Isaacs, H. Teppler, B.-Y. Nguyen, and the BENCHMRK-1 Study Group. 2008. 48-Week results from BENCHMRK-1, a phase III study of raltegravir in patients failing antiretroviral therapy with triple-class resistant HIV-1, abstr. 788, p. 357. Abstr. 15th Conf. Retrovir. Opportunistic Infect., Boston, CA.
9. Craigie, R. 2001. HIV integrase, a brief overview from chemistry to therapeutics. J. Biol. Chem. 276:23213-23216.
10. DeJesus, E., D. Berger, M. Markowitz, C. Cohen, T. Hawkins, P. Ruane, R. Elion, C. Farthing, L. Zhong, A. K. Cheng, D. McColl, and B. P. Kearney for the 183-0101 Study Team. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5.
11. DeJesus, E., C. Cohen, R. Elion, R. Ortiz, L. Maroldo, S. Franson, et al. 2007. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137), abstr. TUPEB032. Abstr. 4th Int. AIDS Soc. Conf. HIV Pathog. Treat. Prev., Sydney, Australia.
12. Deminie, C. A., C. M. Bechtold, D. Stock, M. Alam, F. Djang, A. H. Balch, T.-C. Chou, M. Prichard, R. J. Colonno, and P.-F. Lin. 1996. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob. Agents Che-mother. 40:1346-1351.
13. Egbertson, M. S., H. M. Moritz, J. Y. Melamed, W. Han, D. S. Perlow, M. S. Kuo, M. Embrey, J. P. Vacca, M. M. Zrada, A. R. Cortes, A. Wallace, Y. Leonard, D. J. Hazuda, M. D. Miller, P. J. Felock, K. A. Stillmock, M. V. Witmer, W. Schleif, L. J. Gabryelski, G. Moyer, J. D. Ellis, L. Jin, W. Xu, M. P. Braun, K. Kassahun, N. N. Tsou, and S. D. Young. 2007. A potent and orally active HIV-1 integrase inhibitor. Bioorg. Med. Chem. Lett. 17:1392-1398.
14. Fardis, M., H. Jin, S. Jabri, R. Z. Cai, M. Mish, M. Tsiang, and C. U. Kim. 2006. Effect of substitution on novel tricyclic HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 16:4031-4035.
15. Fikkert, V., A. Hombrouck, B. Van Remoortel, M. De Maeyer, C. Pannecouque, E. De Clercq, Z. Debyser, and M. Witvrouw. 2004. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 18:2019-2028.
16. Fikkert, V., B. Van Maele, J. Vercammen, A. Hantson, B. Van Remoortel, M. Michiels, C. Gurnari, C. Pannecouque, M. De Maeyer, Y. Engelborghs, E. De Clercq, Z. Debyser, and M. Witvrouw. 2003. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol. 77:11459-11470.
17. Grinsztejn, B., B.-Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey, R. D. Isaacs, and the Protocol 005 Team. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet 369:1261-1269.
18. Hazuda, D. J., N. J. Anthony, R. P. Gomez, S. M. Jolly, J. S. Wai, L. Zhuang, T. E. Fisher, M. Embrey, J. P. Guare, Jr., M. S. Egbertson, J. P. Vacca, J. R. Huff, P. J. Felock, M. V. Witmer, K. A. Stillmock, R. Danovich, J. Grobler, M. D. Miller, A. S. Espeseth, L. Jin, I.-W. Chen, J. H. Lin, K. Kassahun, J. D. Ellis, B. K. Wong, W. Xu, P. G. Pearson, W. A. Schleif, R. Cortese, E. Emini, V. Summa, M. K. Holloway, and S. D. Young. 2004. A naphthyridine car-boxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 101:11233-11238.
19. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
20. Hazuda, D. J., M. D. Miller, B. Y. Nguyen, J. Zhao, and the P005 Study Team. 2007. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase 2 study in patients with triple-class resistant HIV-1 infection, abstr. 8. Abstr. 16th Int. HIV Drug Resist. Workshop, Bridgetown, Barbados.
21. Hazuda, D. J., S. D. Young, J. P. Guare, N. J. Anthony, R. P. Gomez, J. S. Wai, J. P. Vacca, L. Handt, S. L. Motzel, H. J. Klein, G. Dornadula, R. M. Danovich, M. V. Witmer, K. A. A. Wilson, L. Tussey, W. A. Schleif, L. S. Gabryelski, L. Jin, M. D. Miller, D. R. Casimiro, E. A. Emini, and J. W. Shiver. 2004. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305:528-532.
22. Hombrouck, A., A. Voet, B. Van Remoortel, C. Desadeleer, M. De Maeyer, Z. Debyser, and M. Witvrouw. 2008. Mutations in HIV-1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob. Agents Chemother. 52:2069-2078.
23. Jin, H., R. Z. Cai, L. Schacherer, S. Jabri, M. Tsiang, M. Fardis, X. Chen, J. M. Chen, and C. U. Kim. 2006. Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors. Bioorg. Med. Chem. Lett. 16:3989-3992.
24. Jin, H., M. Wright, R. Pastor, M. Mish, S. Metobo, S. Jabri, R. Lansdown, R. Cai, P. Pyun, M. Tsiang, X. Chen, and C. U. Kim. 2008. Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs. Bioorg. Med. Chem. Lett. 18:1388-1391.
25. Jones, G., R. Ledford, F. Yu, M. Miller, M. Tsiang, and D. McColl. 2007. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303), abstr. 627, p. 296. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
26. Kafri, T., H. Van Praag, L. Ouyang, F. H. Gage, and I. M. Verma. 1999. A packaging cell line for lentivirus vectors. J. Virol. 73:576-584.
27. King, P. J., and W. E. Robinson, Jr. 1998. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J. Virol. 72:8420-8424.
28. Kodama, E., K. Shimura, Y. Sakagami, Y. Matsuzaki, W. Watanabe, K. Yamataka, M. Sato, M. Kano, S. Ikeda, and M. Matsuoka. 2006. In vitro antiviral activity and resistance profile of a novel HIV integrase inhibitor JTK-303/GS-9137, abstr. H-254, p. 276. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
29. Little, S., G. Drusano, R. Schooley, D. Haas, P. Kumar, S. Hammer, D. McMahon, K. Squires, R. Asfour, D. Richman, J. Chen, A. Saah, R. Leavitt, D. Hazuda, B. Y. Nguyen, and the Protocol 004 Study Team. 2005. Antiret-roviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1 infected patients, abstr. 161, p. 123. Abstr. 12th Conf. Retrovir. Opportunistic Infect., Boston, MA.
30. Margot, N. A., and M. D. Miller. 2005. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. Antivir. Ther. 10:343-348.
31. Markowitz, M., J. O. Morales-Ramirez, B.-Y. Nguyen, C. M. Kovacs, R. T. Steigbigel, D. A. Cooper, R. Liporace, R. Schwartz, R. Isaacs, L. R. Gilde, L. Wenning, J. Zhao, H. Teppler, and the Protocol 004 Study Team. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515.
32. Markowitz, M., B.-Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, C. Kovacs, G. Prada, J. O. Morales-Ramirez, C. S. Crumpacker, R. D. Isaacs, L. R. Gilde, H. Wan, M. D. Miller, L. A. Wenning, H. Teppler, and the Protocol 004 Part II Study Team. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133.
33. McColl, D. J., S. Fransen, S. Gupta, N. Parkin, N. Margot, R. Ledford, J. Chen, S. Chuck, A. K. Cheng, and M. D. Miller. 2007. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase 2 study of elvitegravir (GS-9137). Antivir. Ther. 12(Suppl. 1):S11.
34. Metobo, S. E., H. Jin, M. Tsiang, and C. U. Kim. 2006. Design, synthesis and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring. Bioorg. Med. Chem. Lett. 16:3985-3988.
35. Pani, A., and M. E. Marongiu. 2000. Anti-HIV-1 integrase drugs: how far from the shelf? Curr. Pharm. Des. 6:569-584.
36. Pommier, Y., A. Pilon, K. Bajaj, A. Mazumder, and N. Neamati. 1997. HIV-1 integrase as a target for antiviral drugs. Antivir. Chem. Chemother. 8:463-483.
37. Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
38. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-206.
39. Shimura, K., E. Kodama, Y. Sakagami, Y. Matsuzaki, W. Watanabe, K. Yamataka, Y. Watanabe, Y. Ohata, S. Doi, M. Sato, M. Kano, S. Ikeda, and M. Matsuoka. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82:764-774.
40. Steigbigel, R., P. Kumar, J. Eron, M. Schechter, M. Markowitz, M. Loutfy, J. Zhao, R. Isaacs, B.-Y. Nguyen, H. Teppler, and the BENCHMRK-2 Study Group. 2007. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, inpatients with triple-class resistant virus, abstr. 105bLB, p. 104. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
41. Steigbigel, R., P. Kumar, J. Eron, M. Schechter, M. Markowitz, M. Loutfy, J. Zhao, R. Isaacs, B.-Y. Nguyen, H. Teppler, and the BENCHMRK-2 Study Group. 2008. 48-Week results from BENCHMRK-2, a phase III study of raltegravir (RAL) inpatients failingantiretroviral therapy(ART) withtriple-class resistant HIV-1, abstr. 789, p. 357. Abstr. 15th Conf. Retrovir. Opportunistic Infect., Boston, CA.
42. Thomas, M., and L. Brady. 1997. HIV integrase: a target for AIDS therapeutics. 1997. Trends Biotechnol. 15:167-172.
43. Wai, J., T. Fisher, M. Embrey, M. Egbertson, J. Vacca, D. Hazuda, M. Miller, M. Witmer, L. Gabryelski, and T. Lyle. 2007. New ARV agents, resistance mechanisms, and clinical resistance, abstr. 87, p. 96. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
44. Witmer, M., R. Danovich, Y. Ke, A. Day, L. Gabryelski, L. Ecto, M. Lu, M.-T. Lai, P. McKenna, D. DiStefano, M. Miller, and D. Hazuda. 2007. In vitro resistance selection studies using raltegravir: a novel inhibitor of HIV-1 integrase, abstr. 17. Abstr. 8th Annu. Symp. Antivir. Drug Resist., Richmond, VA.
45. Yoshinaga, T., A. Sato, T. Fujishita, and T. Fujiwara. 2002. S-1360: in vitro activity of a new HIV-1 integrase inhibitor in clinical development, abstr. 8, p. 55. Abstr. 9th Conf. Retrovir. Opportunistic Infect., Seattle, WA.
46. Yu, F., G. S. Jones, M. Hung, A. H. Wagner, H. L. MacArthur, X. Liu, S. Leavitt, M. J. McDermott, and M. Tsiang. 2007. HIV-1 integrase preas-sembled on donor DNA is refractory to activity stimulation by LEDGF/p75. Biochemistry 46:2899-2908.
47. Zolopa, A. R., M. Mullen, D. Berger, P. Ruane, T. Hawkins, L. Zhong, S. Chuck, J. Enejosa, B. Kearney, and A. Cheng. 2007. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients, abstr. 143LB, p. 119. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.